Evidence map›Paper›PMID 24559985›Full record

ArticleBiophysical journal2014

FKBP12.6 activates RyR1: investigating the amino acid residues critical for channel modulation.

Elisa Venturi, Elena Galfré, Fiona O'Brien, Samantha J Pitt, Stuart Bellamy, Richard B Sessions, Rebecca Sitsapesan

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. FKBP12 binds to the cardiac ryanodine receptor with negative cooperativity: implications for heart muscle physiology in health and disease.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Article
  4. Article
  5. Article
  6. FKBP Ligands-Where We Are and Where to Go?Frontiers in pharmacology · 2018
    Review
  7. Article
  8. Review
  9. Review of RyR1 pathway and associated pathomechanisms.Acta neuropathologica communications · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Elisa VenturiDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom.
Elena GalfréDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom.
Fiona O'BrienDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom.
Samantha J PittSchool of Medicine, University of St. Andrews, St. Andrew, United Kingdom.
Stuart BellamyCentre for Nanoscience and Quantum Information (NSQI), University of Bristol, Bristol, United Kingdom.
Richard B SessionsSchool of Biochemistry, University of Bristol, Bristol, United Kingdom.
Rebecca SitsapesanDepartment of Pharmacology, University of Oxford, Oxford, United Kingdom. Electronic address: rebecca.sitsapesan@pharm.ox.ac.uk.
University of Bristol · GBUniversity of Oxford · GBUniversity of St Andrews · GB

Funding

British Heart Foundation FS/08/069/25929British Heart Foundation FS/11/31/28790British Heart Foundation RG/10/14/28576
6 · The paper itself

Abstract

We have previously shown that FKBP12 associates with RyR2 in cardiac muscle and that it modulates RyR2 function differently to FKBP12.6. We now investigate how these proteins affect the single-channel behavior of RyR1 derived from rabbit skeletal muscle. Our results show that FKBP12.6 activates and FKBP12 inhibits RyR1. It is likely that both proteins compete for the same binding sites on RyR1 because channels that are preactivated by FKBP12.6 cannot be subsequently inhibited by FKBP12. We produced a mutant FKBP12 molecule (FKBP12E31Q/D32N/W59F) where the residues Glu(31), Asp(32), and Trp(59) were converted to the corresponding residues in FKBP12.6. With respect to the functional regulation of RyR1 and RyR2, the FKBP12E31Q/D32N/W59F mutant lost all ability to behave like FKBP12 and instead behaved like FKBP12.6. FKBP12E31Q/D32N/W59F activated RyR1 but was not capable of activating RyR2. In conclusion, FKBP12.6 activates RyR1, whereas FKBP12 activates RyR2 and this selective activator phenotype is determined within the amino acid residues Glu(31), Asp(32), and Trp(59) in FKBP12 and Gln(31), Asn(32), and Phe(59) in FKBP12.6. The opposing but different effects of FKBP12 and FKBP12.6 on RyR1 and RyR2 channel gating provide scope for diversity of regulation in different tissues.

Indexed as

Amino Acid SequenceAnimalsBinding SitesHumansIon Channel GatingMolecular Sequence DataMuscle, SkeletalProtein BindingRabbitsRyanodine Receptor Calcium Release ChannelSarcoplasmic ReticulumSheepTacrolimus Binding Protein 1ARyanodine Receptor Calcium Release ChannelTacrolimus Binding Protein 1A

Identifiers

PMID24559985
PMCPMC3945099
OpenAlexW2116661466

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.